The “Celiac Disease – Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Celiac Disease – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 9 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Featured News & Press Releases
- ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention
- ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development
- Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
- ImmusanT Welcomes Ken Truitt as Chief Medical Officer
- ImmusanT Welcomes Ken Truitt, M.D. as Chief Medical Officer
- Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
- Cour Pharmaceuticals Receives FDA Fast Track Designation For TIMP-GLIA
- ImmusanT Provides Year-End Update and Outlines Goals for 2018
- ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase II Studies
- ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in Celiac Disease
- ImmusanT Announces Acceptance of Late Breaking Celiac Interleukin Data at United European Gastroenterology Week
- ImmusanT to Present New Nexvax2 Dosing Data at United European Gastroenterology Week
- Bioniz Therapeutics Presents Data Demonstrating the Synergistic Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis
- ImmusanT Presents Data from Multiple Studies Supporting Continued Development of Nexvax
- ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science
- Amgen Inc.
- Calypso Biotech SA
- IB Pharmaceuticals Inc.
- ImmusanT Inc.
- Intrexon Corp.
- Takeda Pharmaceutical Co Ltd.
- Topas Therapeutics GmbH
- Zedira GmbH
Key Topics Covered
2. Report Coverage
3. Celiac Disease – Overview
4. Celiac Disease – Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Celiac Disease – Therapeutics Assessment
11. Celiac Disease – Companies Involved in Therapeutics Development
12. Celiac Disease – Drug Profiles
13. Celiac Disease – Dormant Projects
14. Celiac Disease – Product Development Milestones
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fzxrht/celiac_disease?w=4.
Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Disorders Drugs, Gastrointestinal